|
AI-based radiomics model for predicting immune checkpoint inhibitor–related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study. |
|
|
No Relationships to Disclose |
|
|
Employment - Picture Health |
Travel, Accommodations, Expenses - Picture Health |
|
|
Employment - Picture Health |
Stock and Other Ownership Interests - Picture Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Picture Health; Sirona Medical |
Stock and Other Ownership Interests - Picture Health; Sirona Medical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Galvanize Therapeutics |
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda |
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Picture Health; Tempus |
Stock and Other Ownership Interests - Picture Health; Tempus |
|
|
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Foundation Medicine; Guardant Health; Immuneoncia; Lilly; Lunit; Roche/Genentech; Takeda; Tempus |
Speakers' Bureau - AstraZeneca; BMS; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Lilly; Merck |
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio |